Can BioShield effectively procure medical countermeasures that safeguard the nation?: hearing before the Subcommittee on Emerging Threats, Cybersecurity, and Science and Technology of the Committee on Homeland Security, House of Representatives, One Hundred Tenth Congress, April 18, 2007, Volume 4
What people are saying - Write a review
We haven't found any reviews in the usual places.
The Honorable James R Langevin a Representative in Congress From
Mr Richard Hollis Chief Executive Officer HollisEden Pharmaceuticals
Anthony Fauci M D Director National Institutes of allergy and Infectious
2 other sections not shown
acquisition acute radiation syndrome additional advance purchase contract advanced development Advanced Research agency agents anthrax disease anthrax toxins anthrax vaccine antibiotics assessment award BARDA biodefense biological BioShield eligible BioShield legislation BioShield program bioterrorism CBER CBRN Chairman chemical Christensen clinical hold clinical trials committee companies competitive range Congress Davis devel doses of ABthrax drug candidate effective emergency Etheridge evaluation Fauci FDA approved funding Goodman Hollis Hollis-Eden Homeland Security Human Genome Sciences implementation industry infectious diseases investigational product issues Jackson Lee Langevin licensure Lungren manufacturing material threat determinations McCaul medical countermeasures ment million NEUMUNE nuclear opment Pandemic Parker potential private sector procurement product development Project BioShield Act public health questions radiological requirements research and development response risk role Runge safety statement strategic national stockpile studies subcommittee terrorist testimony Thank therapeutic Valley of Death VaxGen witnesses